Neuroactive steroids, compositions, and uses thereof
Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
1. A method for treating post-partum depression in a human subject in need thereof, the method comprising administering allopregnanolone at a dosing regimen over a time period of about 60 hours, wherein the dosing regimen comprises a continuous infusion of:
30 μg/kg/hour of allopregnanolone from about hour 0 to about hour 4;
60 μg/kg/hour of allopregnanolone from about hour 4 to about hour 24;
90 μg/kg/hour of allopregnanolone from about hour 24 to about hour 52;
60 μg/kg/hour of allopregnanolone from about hour 52 to about hour 56; and
30 μg/kg/hour of allopregnanolone from about hour 56 to about hour 60.
2. The method of claim 1 , wherein allopregnanolone is in a sterile aqueous solution comprising allopregnanolone and sulfobutylether-β-cyclodextrin.
3. The method of claim 2 , wherein the sterile aqueous solution is buffered with citrate.
4. The method of claim 3 , wherein the sterile aqueous solution comprises about 0.1 mg/mL to about 10 mg/mL of allopregnanolone.
5. The method of claim 4 , wherein the sterile aqueous solution comprises about 0.1 mg/mL to about 5 mg/mL of allopregnanolone.
6. The method of claim 5 , wherein the sterile aqueous solution comprises about 1 mg/mL of allopregnanolone.
7. The method of claim 3 , wherein the sterile aqueous solution comprises about 1% to about 30% by weight of sulfobutylether-β-cyclodextrin per volume of sterile aqueous solution.
8. The method of claim 7 , wherein the sterile aqueous solution comprises about 1% to about 15% by weight of sulfobutylether-β-cyclodextrin per volume of sterile aqueous solution.
9. The method of claim 8 , wherein the sterile aqueous solution comprises about 1% to about 5% by weight of sulfobutylether-β-cyclodextrin per volume of sterile aqueous solution.
10. The method of claim 9 , wherein the sterile aqueous solution comprises about 5% by weight of sulfobutylether-β-cyclodextrin per volume of sterile aqueous solution.